InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,459.10
(
1.11%
)
US TECH 100
18,514.00
(
1.00%
)
Dow Jones
40,589.34
(
1.64%
)
Brent Oil
79.75
(
0.00%
)
Bitcoin
68,143.85
(
0.50%
)
Post# of 252706
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 120143
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 252013

Monday, 06/03/2024 3:00:06 PM

Monday, June 03, 2024 3:00:06 PM

Post# of 252706
Re: GPCR /GSBR-1290 tolerability

As expected for the GLP1-RA drug class, leading adverse events were gastrointestinal-related and the two most common AEs were nausea and vomiting.

This excerpt from GPCR's PR today is somewhat misleading insofar as 89% of patients in the treatment arm experienced nausea and 62% experienced vomiting—see slide #16 at https://ir.structuretx.com/static-files/775ca535-9bd3-455e-a41a-44dea273c90d .

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up